• Explore /
  • Poster
  • / Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type <em>KRAS</em> metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Kentaro Yamazaki , Hiroyuki Uetake , Takeshi Kato , Eiji Oki , Takeharu Yamanaka , Yasuo Ohashi , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

UMIN000011294

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3662)

DOI

10.1200/jco.2014.32.15_suppl.tps3662

Abstract #

TPS3662

Poster Bd #

118A

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Yasushi Tsuji

First Author: Samuel A. Jacobs

First Author: Heinz-Josef Lenz